Not provided
Not provided
Not provided
Not provided
Not provided
Strategy review
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of Canadá association in the treatment of chronic pain
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Canadá association | Experimental | The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows: 1 tablet Canadá, oral; 1 placebo tablet of tramadol, oral; 1 placebo tablet of dipyrone, oral. |
|
| Tramadol | Active Comparator | The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows: 1 tablet tramadol, oral; 1 placebo tablet of Canadá, oral; 1 placebo tablet of dipyrone, oral. |
|
| Dipyrone | Active Comparator | The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows: 1 tablet dipyrone, oral; 1 placebo tablet of tramadol, oral; 1 placebo tablet of Canadá, oral. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Canadá | Drug | Canadá association 1 tablet twice a day |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Difference in pain intensity assessed by the VAS scale | Change from baseline in the pain intensity escores assessed in medical visits. | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events | Incidence and severity of adverse events recorded during the study | 16 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D059350 | Chronic Pain |
| D000377 | Agnosia |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004177 | Dipyrone |
| D014147 | Tramadol |
| ID | Term |
|---|---|
| D000632 | Aminopyrine |
| D047069 | Pyrazolones |
| D011720 | Pyrazoles |
| D001393 | Azoles |
| D006573 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Canadá placebo |
| Other |
Placebo of Canadá association 1 tablet twice a day |
|
| Dipyrone | Drug | Dipyrone 1 tablet twice a day |
|
| Dipyrone placebo | Other | Placebo of dipyrone 1 tablet twice a day |
|
| Tramadol hydrochloride | Drug | Tramadol 1 coated tablet twice a day |
|
| Tramadol hydrochloride placebo | Other | Placebo of tramadol 1 coated tablet twice a day |
|
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009422 | Nervous System Diseases |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D003511 | Cyclohexanols |
| D000441 | Hexanols |
| D005233 | Fatty Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D004123 | Dimethylamines |
| D008744 | Methylamines |
| D000588 | Amines |
| D008055 | Lipids |